Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin’s lymphoma

Cella, Laura; Liuzzi, Raffaele; Conson, Manuel; Torre, Gabriella Della; Caterino, Michele; Rosa, Nicola; Picardi, Marco; Camera, Luigi; Solla, Raffaele; Farella, A.; Salvatore, Marco; Pacelli, Roberto

doi:10.1016/j.radonc.2011.08.040

Cited by 44 publications

(34 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk of cardiac disease is directly related to radiation doses. 23,24 In a study of 1132 pediatric HL survivors treated on 5 consecutive German-Austrian pediatric trials, the 25-year cumulative incidence of cardiac disease in the group with a mediastinal radiation dose of 36 Gy was 21% and the risk decreased significantly to 10%, 6%, 5%, and 3% in those with lower mediastinal radiation doses of 30, 25, 20, and 0 Gy, respectively (P , .001). 23 On multivariable analysis, mediastinal radiation dose was the only significant factor predicting for cardiac disease-free survival (P 5 .0025).…”

Section: Cardiovascular Diseasementioning

confidence: 99%

“…6,8 Additional research efforts on correlating radiation dosimetric parameters of specific organs with late effects would improve our understanding of the relationship between radiation dosevolume and long-term risks and guide future radiation treatment planning. 24,34 There are emerging data on an association between anthracyclines and, not just cardiac risk, but also solid tumors, and further follow-up is needed to confirm the findings. 52 Finally, as new targeted agents are adopted for HL, their long-term risks need to be fully assessed.…”

Section: Future Directionsmentioning

confidence: 99%

See 1 more Smart Citation

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

2014

Blood

View full text Add to dashboard Cite

Long-term survivors of Hodgkin lymphoma (HL) are at an increased risk for a range of late complications, with subsequent malignant neoplasm and cardiovascular disease representing the 2 leading causes of death in these patients. Raising awareness, close follow-up, and adoption of selected earlydetection and risk-reduction strategies may help to reduce the adverse impact of these late effects on patients. This chapter reviews known long-term complications of HL therapy, risk factors, and the timing of their occurrence. Where available, data on the efficacy of screening for selected late effects of HL are presented. Current evidence-based and consensus-based recommendations on follow-up of longterm HL survivors are also reviewed. As HL therapy evolves over time, late effects and implications on follow-up of patients treated in the contemporary era should be considered and opportunities for future research should be explored. (Blood. 2014; 124(23):3373-3379)

show abstract

Section: Cardiovascular Diseasementioning

confidence: 99%

Section: Future Directionsmentioning

confidence: 99%

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

2014

Blood

View full text Add to dashboard Cite

show abstract

“…The risk of cardiac disease is directly related to radiation doses. 23,24 In a study of 1132 pediatric HL survivors treated on 5 consecutive German-Austrian pediatric trials, the 25-year cumulative incidence of cardiac disease in the group with a mediastinal radiation dose of 36 Gy was 21% and the risk decreased significantly to 10%, 6%, 5%, and 3% in those with lower mediastinal radiation doses of 30, 25, 20, and 0 Gy, respectively (P Ͻ .001). 23 On multivariable analysis, mediastinal radiation dose was the only significant factor predicting for cardiac disease-free survival (P ϭ .0025).…”

Section: Cardiovascular Diseasementioning

confidence: 99%

“…6,8 Additional research efforts on correlating radiation dosimetric parameters of specific organs with late effects would improve our understanding of the relationship between radiation dose-volume and long-term risks and guide future radiation treatment planning. 24,34 There are emerging data on an association between anthracyclines and, not just cardiac risk, but also solid tumors, and further follow-up is needed to confirm the findings. 52 Finally, as new targeted agents are adopted for HL, their long-term risks need to be fully assessed.…”

Section: Future Directionsmentioning

confidence: 99%

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

2014

Hematology

View full text Add to dashboard Cite

Long-term survivors of Hodgkin lymphoma (HL) are at an increased risk for a range of late complications, with subsequent malignant neoplasm and cardiovascular disease representing the 2 leading causes of death in these patients. Raising awareness, close follow-up, and adoption of selected early-detection and risk-reduction strategies may help to reduce the adverse impact of these late effects on patients. This chapter reviews known long-term complications of HL therapy, risk factors, and the timing of their occurrence. Where available, data on the efficacy of screening for selected late effects of HL are presented. Current evidence-based and consensus-based recommendations on follow-up of long-term HL survivors are also reviewed. As HL therapy evolves over time, late effects and implications on follow-up of patients treated in the contemporary era should be considered and opportunities for future research should be explored. Learning Objectives• To review the risk of and risk factors for late effects after HL therapy • To discuss data on the efficacy of screening strategies for selected late effects of HL • To summarize current follow-up recommendations for longterm HL survivors

show abstract

“…Most studies had very poor dosimetry, none had individual dosimetry and nearly all relied on mean heart dose estimates. Only few studies attempted to determine Klaus Rüdiger Trott klaustrott@yahoo.it 1 UCL Cancer Institute, University College London, London, UK partial heart doses in relation to specific radiation-induced heart diseases [16][17][18][19].…”

mentioning

confidence: 99%

Some considerations for future research into the risks of radiation-induced cardiovascular diseases

Trott

2016

Strahlenther Onkol

View full text Add to dashboard Cite

Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin’s lymphoma

Cited by 44 publications

References 32 publications

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

Some considerations for future research into the risks of radiation-induced cardiovascular diseases

Contact Info

Product

Resources

About